Analysts and shareholders look forward with bated breath to the prospects of Geron Corp. (NASDAQ:GERN), and in particular a pair of articles came out recently evaluating the long-term prospects of this company.
And they couldn’t be further apart in their conclusions. The first, MedTechBio’s “Little Geron May Soon Be Nipping At the Heels of Celgene And Incyte,” offers a most bullish of bullish takes, going so far as to suggest that, upon its likely approval, imetelstat revenues will continue very deeply into the likes of pharma juggernauts lenalidomide and ruxolitinib, each worth many billions of dollars in sales each year.
To say the least, if GERN catches a significant portion of this, any shareholder invested at these levels will be quite well compensated.
I thought this was an interesting, but flawed, thesis, and I highly recommend you read it. MedTechBio is very clearly highly enthusiastic about GERN, but I do not get the impression that he/she has failed to do adequate research on the matter.
Compare that with the more recent bearish screed, “Geron: Imetelstat's History Of Deaths And Safety Issues,” which is a much more back-looking “short” tale that focuses on historical toxicity of imetelstat before arriving at a valuation for GERN of 80% what it is today.
Well, I would like to publicly address a few concerns I have with both articles, as a generally disinterested observer. I have no financial interest in GERN personally, although I did include it in my pilot run of a “No BS” plan, with the prediction that it will rise in price.
Qualms with the (overly) bullish position
MedTechBio makes clear a few central points in the positive outlook for GERN. Namely, Celgene (NASDAQ:CELG) will come to regret their recent acquisition of Impact Biosciences for their JAK inhibitor fedratinib, because imetelstat, if approved, should
